Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-0096
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry ; volume:19 ; number:1 ; day:21 ; month:8 ; year:2021 ; pages:1-10 ; date:12.2021
Pediatric rheumatology ; 19, Heft 1 (21.8.2021), 1-10, 12.2021
- Urheber
-
Beukelman, Timothy
Lougee, Aimee
Matsouaka, Roland A.
Collier, David
Rumsey, Dax G.
Schenfeld, Jennifer
Stryker, Scott
Twilt, Marinka
Kimura, Yukiko
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12969-021-00625-y
- URN
-
urn:nbn:de:101:1-2021110720420313302668
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Beukelman, Timothy
- Lougee, Aimee
- Matsouaka, Roland A.
- Collier, David
- Rumsey, Dax G.
- Schenfeld, Jennifer
- Stryker, Scott
- Twilt, Marinka
- Kimura, Yukiko
- SpringerLink (Online service)
Ähnliche Objekte (12)
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans
Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey
Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis
Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry
Research priorities in pediatric rheumatology: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus
Correction: Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease
Familial autoimmunity in the childhood arthritis and rheumatology research alliance registry
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans
Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey
Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis
Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry
Research priorities in pediatric rheumatology: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus
Correction: Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease
Familial autoimmunity in the childhood arthritis and rheumatology research alliance registry
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans
Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey
Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis
Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry
Research priorities in pediatric rheumatology: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus
Correction: Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease